A key factor in initiating and operating the immune system against tumour cells, the dendritic cell (DC) has been regarded as the next possible breakthrough in new cancer therapy. However, the results of more than 15 years of clinical studies with DC vaccine revealed the difficulties fulfilling this expectation. Evidence has disclosed that the DC activation required for proper tumour-specific effector CD4+ and CD8+ T cell stimulation is inhibited in the micro-environment of tumour. Studies have further reported that DC phenotypes in tumour tissue and draining lymph nodes are mostly immature, which results in regulatory immune responses. Also, the existence of MDSCs and TAMs adversely affect both DC function and immune suppression in the cancer-environment. In this review, efforts to overcome the tumour or host-dependent hindering which inhibit the effect of cancer vaccine will be discussed. The combination therapy of cancer with DC vaccine and other immune modulators may improve the clinical efficacy.
The role of the dendritic cell (DC) is at the centre of the immune system by initiating, progressing and regulating the responses against pathogens, include tumours. After the first successful clinical achievement in DC-based immunotherapy trials in follicular lymphoma and melanoma in the mid-1990s, 1,2 the DC vaccine used to treat patients with cancer such as melanoma, lymphoma and renal cell carcinoma. [3] [4] [5] [6] [7] However clinical expectations have not been fulfilled due to an overall clinical response rates of under 10-15 %, the usual response rates observed in various types of immunotherapies. [6] [7] [8] [9] [10] [11] The meta analysis performed with 906 prostate and renal cell cancer (RCC) patients in 29 separate DC vaccine clinical trials revealed the objective response rates, 7.7 % in prostate cancer and 12.7 % in RCC. 12 If the stable disease rate was combined as clinical benefit rate (CBR), much better response rate was counted (54 % in prostate cancer and 48 % in RCC). Although the clinical expectation has not been satisfied, the outcomes of many clinical trials with tumour antigen-loaded conventional DCs have provided proof that therapeutic immunity can be elicited. [13] [14] [15] And statistically significant effect of DC-mediated cellular immune response and of DC dose on CBR was proved in meta-analysis. 12 The clinical data has helped to establish a standard for properly activated DCs with appropriate form and doses of loading antigens.These activated DCs can migrate to the lymph nodes which then initiate and expand tumour-specific CD4+ and CD8+ T cell responses and later induce meaningful therapeutic responses in patients. analysed DC vaccine problems in their publications. 4, 6, 13, 15, [21] [22] [23] One of the efforts is using allogeneic cells, since the DCs isolated from cancer patients express impaired characters for generation of the tumour-specific immunity. 24 Thus, without further discussing about the DC vaccine quality, tumour tissue or host side hindering factors and the possibility of improving antitumour immune-therapeutic efficacy will be discussed in this review. [32] [33] Typical inflammatory mediators of tumour-induced DC dysfunctions include; IL-10, TGF-, VEGF, IL-6 and prostanoids such as PGE2-634-37.
Dendritic Cells in Cancer Patients
These mediators are produced from either the tumour itself or the infiltrated host factors including MDSCs and TAMs. In this milieu, DCs are having trouble maturing, expressing the co-stimulatory molecules needed for T cell activation, and producing the cytokines needed to support tumour specific effector T cell activation and survival. [38] [39] [40] [41] Tumour-related malfunctions of DCs are noted in patients with ovarian, breast, melanoma, renal cell, prostate carcinoma [42] [43] [44] [45] and in the blood of head and neck, lung and breast cancer patients. 38, 46 The major intracellular signalling pathway required for DC activation and final maturation in the immunosuppressive milieu of the tumour micro-environment is STAT3. 47 
Inflammatory Nature of Tumour Micro-environment
The development of about 15-20 % of malignancies worldwide are known to be related to chronic inflammation, including oesophageal, gastric, hepatic, pancreatic and colorectal cancer. 53 Inflammatory mediators produced by the tumour cell can create an inflammatory micro-environment and cause both leukocyte recruitment and angiogenesis. [54] [55] [56] Also, these inflammatory milieus can help tumour cell survival, motility and chemotaxis. For example, breast cancer cells are known to produce the inflammatory chemokines CCL2 and CCL5, which are poorly expressed in normal breast cells. These chemokines recruit TAMS and inhibit potential antitumour effector T cells. 57 In other words, the immunosuppressive tumour micro-environment is created by the inflammatory nature of tumours and an infiltration of assorted leukocytes, in particular MDSCs and TAMs. This infiltration leads to the suppression of the DC-induced effectors, CD4+ and CD8+ T cell responses and the induction of T reg .
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MDSCs in the Tumour Micro-environment
The mechanisms which chronic inflammation promotes the onset and development of tumours are differentiated into non-immunological and immunological ways. 58 The non-immune mechanisms include:
1) the production of reactive oxygen species which cause DNA mutation, 2) the production of pro-angiogenic factors, like VEGF which promote tumour neo-vascularisation 3) the production of matrix metalloproteases which facilitate invasion and metastasis. [59] [60] [61] The predominant immune mechanism is the disturbance of myelopoiesis 
Improvement of Clinical Efficacy of the Dendritic Cells Vaccine
Considering the inflammatory tumour micro-environment and 
